ARTICLE | Emerging Company Profile
Skin-to-skin
How MatriSys is harnessing the skin microbiome to treat skin conditions
March 30, 2018 5:25 PM UTC
MatriSys Bioscience Inc. is developing topical formulations of bacteria derived from the skin microbiome to treat atopic dermatitis and other dermatological conditions, which could be safer than more advanced and marketed therapies that work by inducing immune suppression.
According to President and CEO Mark Wilson, current atopic dermatitis treatments either address skin inflammation by suppressing the immune system, which could lead to increased risk of infectious disease, or involve topical creams that form a barrier between the skin and external irritants, but do not address the root cause of inflammation...
BCIQ Company Profiles